Nektar Therapeutics Announces New Drug Application for NKTR-181 Accepted for Review by FDA

SAN FRANCISCO, July 30, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has filed and accepted for review the company ' s New Drug Application (NDA) for NKTR-181 for the...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news